GSK's Triple Combo COPD Drug Gets Europe Okay

 
• By Kevin Grogan

Europe's regulators have followed their US counterparts and given the green light to GSK's Trelegy. Now the company is hoping that having the first once-daily single inhaler triple therapy for COPD will boost its respiratory business.

Birthday cake
GSK hopes payors will see the benefits of three-in-one COPD therapy • Source: Shutterstock

More from Respiratory

More from Therapy Areas